S1320: A Randomized, Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E K Mutant Melanoma - Regional Cancer Care Associates LLC

Clinical Trials

S1320: A Randomized, Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E K Mutant Melanoma

Type of Cancer
Skin and Soft Tissue
Locations
Hackensack
Sponsor
SWOG
Protocol Number
SWOG S1320
Cancer Diagnosis
To Learn More Call
201-510-0910